Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis
Top Cited Papers
- 1 July 2009
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 9 (7), 409-417
- https://doi.org/10.1016/s1473-3099(09)70136-7
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretroviralsBulletin of the World Health Organization, 2008
- Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modificationAIDS, 2008
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South AfricaClinical Infectious Diseases, 2008
- Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in MalawiThe Lancet, 2008
- Twenty‐four‐week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first‐line antiretroviral therapy: a randomized double‐blind trial (NORA)*Tropical Medicine & International Health, 2008
- Performance of a World Health Organization first‐line regimen (stavudine/lamivudine/nevirapine) in antiretroviral‐naïve individuals in a Western settingHIV Medicine, 2007
- HIV-1 Viral Load Assays for Resource-Limited SettingsPLoS Medicine, 2006
- Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAARTPLoS Medicine, 2006
- Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence TrialClinical Infectious Diseases, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004